TherapeuticsMD, Inc. (NASDAQ: TXMD) is a micro-cap pharmaceutical royalty company based in Boca Raton, Florida. After divesting its commercial operations in 2022–2023, it licensed its FDA-approved women's health products — IMVEXXY, BIJUVA, and ANNOVERA — to Mayne Pharma and now collects most of its revenue from license fees and royalties, with no material research and development or sales force of its own.
TXMD has essentially dropped off mainstream sell-side coverage. MarketBeat lists only a single current rating and no usable consensus price target, while other aggregators carry one legacy $5.00 figure that is several years stale. Because there is no credible set of individually attributed, current analyst targets, this article does not force an "analyst consensus" and instead relies on a fallback objective grounded in identifiable public discussion.
The $2.50 figure corresponds to the most recently reported analyst note on the company — a Buy rating with a $2.50 price target cited in a March 2026 company press release. It is also consistent with the stock's own recent trading history, since shares reached roughly $2.95 during the past year. For context only, much older coverage once carried targets as high as $11, but those reflect a different business and era.
Shares have recently traded near $1.85, within a 52-week range that has extended from below $1.00 to about $2.95. Reaching $2.50 would require a gain of roughly 35% — a substantial move for a thinly traded micro-cap, though not unprecedented given the stock's own history above that level earlier in the year.
The potential path runs through execution of the royalty strategy. In full-year 2025, the company narrowed its net loss to about $0.7 million, or $0.06 per share, from $2.3 million a year earlier, while license revenue rose roughly 72% to $3.0 million and operating expenses fell. With about $7.5 million in cash at year-end and an ongoing review of strategic alternatives — including possible M&A or an asset sale — the fundamental story is less about quarterly growth than about the value of its royalty stream and the outcome of any corporate transaction.
Technical signals in a stock this thinly traded should be treated cautiously. The most durable reference points are the 52-week high near $2.95, which stands as a significant overhead resistance level, and the $2.50 objective itself, which coincides with a prior zone the stock has traded through. On the downside, the $1.70–$1.75 area has acted as a short-term support level in recent sessions, with the lower end of the yearly range below $1.00 representing a much deeper floor.
Most analyst price objectives conventionally reflect a roughly 12-month horizon, but the specific horizon for the $2.50 note is not disclosed. Given the company's micro-cap profile, investors should monitor quarterly royalty and license revenue, cash balances, any update on the strategic-alternatives review, and any new analyst initiation or target change — all of which could shift the market's view of the royalty stream's worth. FDA or commercial developments at the licensee, Mayne Pharma, also matter indirectly because they drive the underlying product sales.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a low-liquidity name like TXMD, such tools can help traders track shifting momentum and identify changing trends more efficiently. Traders can use these signals to discover new opportunities, monitor existing positions, and respond more quickly to evolving market structure.
Whether TXMD reaches $2.50 depends less on a formal analyst consensus — none currently exists — than on execution of a concentrated royalty model and the outcome of its strategic review. A roughly 35% move is substantial, yet the stock has already traded above that level in the past year, so the target is not out of reach historically. The supportive case rests on growing royalty revenue, a narrowing loss, and a clean balance sheet; the counter-case rests on single-licensee concentration, thin liquidity, and the absence of any guaranteed corporate catalyst. Investors should watch royalty results, cash levels, and any deal news before drawing conclusions about the $2.50 objective.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TXMD has been loosely correlated with LIEN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TXMD jumps, then LIEN could also see price increases.
| Ticker / NAME | Correlation To TXMD | 1D Price Change % | ||
|---|---|---|---|---|
| TXMD | 100% | -1.62% | ||
| LIEN - TXMD | 36% Loosely correlated | -1.31% | ||
| IMCC - TXMD | 24% Poorly correlated | -3.83% | ||
| ACB - TXMD | 23% Poorly correlated | -1.19% | ||
| BCRX - TXMD | 22% Poorly correlated | +0.39% | ||
| SBFM - TXMD | 22% Poorly correlated | +3.27% | ||
More | ||||
| Ticker / NAME | Correlation To TXMD | 1D Price Change % |
|---|---|---|
| TXMD | 100% | -1.62% |
| Pharmaceuticals: Generic industry (81 stocks) | -6% Poorly correlated | -0.94% |